HOME | Alphawatch

top of page

Stock Exchange

Roivant & Immunovant (ROIV & IMVT): Unlocking the Potential of Targeted Immunology

Roivant & Immunovant (ROIV & IMVT): Unlocking the Potential of Targeted Immunology

Roivant & Immunovant (ROIV & IMVT): Unlocking the Potential of Targeted Immunology

Jonathan Poyer

6 minutes ago3 min read

Insmed (INSM): From Clinical Breakthrough to Commercial Breakout

Insmed (INSM): From Clinical Breakthrough to Commercial Breakout

Insmed (INSM): From Clinical Breakthrough to Commercial Breakout

Jonathan Poyer

4 hours ago3 min read

Scholar Rock (SRRK): A New Frontier in Treating Spinal Muscular Atrophy

Scholar Rock (SRRK): A New Frontier in Treating Spinal Muscular Atrophy

Scholar Rock (SRRK): A New Frontier in Treating Spinal Muscular Atrophy

Jonathan Poyer

4 hours ago2 min read

The Patent Cliff: Why Big Pharma Can't Wait

The Patent Cliff: Why Big Pharma Can't Wait

The Patent Cliff: Why Big Pharma Can't Wait

Jonathan Poyer

6 days ago2 min read

Biotech M&A: Nearly $8 Billion in Just Five Weeks

Biotech M&A: Nearly $8 Billion in Just Five Weeks

Biotech M&A: Nearly $8 Billion in Just Five Weeks

Jonathan Poyer

7 days ago2 min read

Manhattan Associates (MANH): The Software Behind Automation Is Having a Moment

Manhattan Associates (MANH): The Software Behind Automation Is Having a Moment

Manhattan Associates (MANH): The Software Behind Automation Is Having a Moment

Jonathan Poyer

Oct 302 min read

Housing Credit: Strong Collateral, A Strained Consumer, and Two Very Different Housing Markets

Housing Credit: Strong Collateral, A Strained Consumer, and Two Very Different Housing Markets

Housing Credit: Strong Collateral, A Strained Consumer, and Two Very Different Housing Markets

Jonathan Poyer

Oct 294 min read

argenx (ARGX): $1.7 Billion in Quarterly Sales — And Five Potential Launches in 2027

argenx (ARGX): $1.7 Billion in Quarterly Sales — And Five Potential Launches in 2027

argenx (ARGX): $1.7 Billion in Quarterly Sales — And Five Potential Launches in 2027

Jonathan Poyer

Oct 272 min read

Amgen & AstraZeneca: Nearly 69% Achieve Remission in Phase 3 — But What Does That Mean for Patients?

Amgen & AstraZeneca: Nearly 69% Achieve Remission in Phase 3 — But What Does That Mean for Patients?

Amgen & AstraZeneca: Nearly 69% Achieve Remission in Phase 3 — But What Does That Mean for Patients?

Jonathan Poyer

Oct 224 min read

Roivant: A 56% Reduction in Pulmonary Vascular Resistance — What Does It Mean?

Roivant: A 56% Reduction in Pulmonary Vascular Resistance — What Does It Mean?

Roivant: A 56% Reduction in Pulmonary Vascular Resistance — What Does It Mean?

Jonathan Poyer

Oct 223 min read

Synopsys (SNPS): Amazon, OpenAI and a New Growth Outlook

Synopsys (SNPS): Amazon, OpenAI and a New Growth Outlook

Synopsys (SNPS): Amazon, OpenAI and a New Growth Outlook

Jonathan Poyer

Oct 92 min read

The Ondas Paradox (ONDS): Huge Growth. So Why Isn't the Stock Cooperating?

The Ondas Paradox (ONDS): Huge Growth. So Why Isn't the Stock Cooperating?

The Ondas Paradox (ONDS): Huge Growth. So Why Isn't the Stock Cooperating?

Jonathan Poyer

Oct 22 min read

bottom of page